TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123...
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and...
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel...
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results PR Newswire SAN DIEGO, May 14, 2024...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.